

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28370 A1

- (51) International Patent Classification⁷: **A61K 9/16**, 9/50, B01J 13/02
- (21) International Application Number: PCT/SE01/02164
- (22) International Filing Date: 5 October 2001 (05.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0003615-2 6 October 2000 (06.10.2000) SE
60/260,455 8 January 2001 (08.01.2001) US
- (71) Applicant (for all designated States except US):
BIOGLAN AB [SE/SE]; P.O. Box 50310, S-202 13 Malmö (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **JÖNSSON, Monica** [SE/SE]; Sigvard Grubbcs gata 1, S-230 40 Bara (SE). **GUSTAVSSON, Nils, Ove** [SE/SE]; Hippodromvägen 7, S-246 50 Löddeköpinge (SE). **LAAKSO, Timo** [SE/GB]; 2 Rectory Road, Campton, Bedfordshire SG17 5PF (GB). **RESLOW, Mats** [SE/SE]; Bondvägen, S-227 38 Lund (SE).
- (74) Agent: **AWAPATENT AB**; Box 45086, S-104 30 Stockholm (SE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, FF (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/28370 A1

(54) Title: BIODEGRADABLE MICROPARTICLES FOR CONTROLLED RELEASE ADMINISTRATION, WITH PURIFIED AMYLOPECTIN-BASED STARCH OF REDUCED MOLECULAR WEIGHT

(57) Abstract: A process for producing parenterally administrable microparticles, in which an at least 20 % by weight aqueous solution of purified amylopectin-based starch of reduced molecular weight is prepared, the solution is combined with biologically active substance, an emulsion of starch droplets is formed in an outer phase of polymer solution, the starch droplets are made to gel, and the gelled starch particles are dried. A release-controlling shell is optionally also applied to the particles. Microparticles which essentially consist of said starch, have an amino acid content of less than 50 µg and have no covalent chemical cross-linking.

Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight.

TECHNICAL FIELD

5 The present invention lies within the field of galenic formulations for the administration of biologically active substances, more precisely microparticles for controlled release intended for parenteral administration of biologically active
10 substances, especially drugs. More specifically, it relates to a novel production process for such particles containing a biologically active substance and to novel particles for controlled release obtainable thereby.

15 BACKGROUND TO THE INVENTION

 Many drugs have to be administered by injection, since they are either subjected to degradation or are insufficiently absorbed when they are given, for example, orally or nasally or by the rectal route. A drug
20 preparation intended for parenteral use has to meet a number of requirements in order to be approved by the regulatory authorities for use on humans. It must therefore be biocompatible and biodegradable and all used substances and their degradation products must be non-
25 toxic. In addition, particulate drugs intended for injection have to be small enough to pass through the injection needle, which preferably means that they should be smaller than 200 μm . The drug should not be degraded in the preparation to any great extent during production or
30 storage thereof or after administration and should be released in a biologically active form with reproducible kinetics.

 One class of polymers which meets the requirements of biocompatibility and biodegradation into harmless end
35 products is the linear polyesters based on lactic acid, glycolic acid and mixtures thereof. These polymers will

also hereinafter be referred to as PLGA. PLGA is degraded by ester hydrolysis into lactic acid and glycolic acid and has been shown to possess excellent biocompatibility. The innocuous nature of PLGA can be exemplified, moreover, by the approval by the regulating authorities, including the US Food and Drug Administration, of several parenteral delayed release preparations based on these polymers.

Parenterally administrable delayed release products currently on the market and based on PLGA include Decapeptyl™ (Ibsen Biotech), Prostag SR™ (Lederle), Decapeptyl® Depot (Ferring) and Zoladex® (Zeneca). The drugs in these preparations are all peptides. In other words, they consist of amino acids condensed into a polymer having a relatively low degree of polymerization and they do not have any well-defined three-dimensional structure. This, in turn, usually allows the use of relatively stringent conditions during the production of these products. For example, extrusion and subsequent size-reduction can be utilized, which techniques would probably not be allowed in connection with proteins, since these do not, generally speaking, withstand such stringent conditions.

Consequently, there is also a need for controlled release preparations for proteins. Proteins are similar to peptides in that they also consist of amino acids, but the molecules are larger and the majority of proteins are dependent on a well-defined three-dimensional structure as regards many of their properties, including biological activity and immunogenicity. Their three-dimensional structure can be destroyed relatively easily, for example by high temperatures, surface-induced denaturation and, in many cases, exposure to organic solvents. A very serious drawback connected with the use of PLGA, which is an excellent material per se, for delayed release of proteins is therefore the need to use organic solvents to dissolve the said PLGA, with the attendant risk that the stability

of the protein will be compromised and that conformation changes in the protein will lead to an immunological reaction in the patient, which can produce both a loss of therapeutic effect, through the formation of inhibitory
5 antibodies, and toxic side effects. Since it is extremely difficult to determine with certainty whether a complex protein has retained its three-dimensional structure in every respect, it is very important to avoid exposing the protein to conditions which might induce conformation
10 changes.

Despite intense efforts aimed at modifying the PLGA technology in order to avoid this inherent problem of protein instability during the production process, progress within this field has been very slow, the main
15 reason probably being that the three-dimensional structures for the majority of proteins are far too sensitive to withstand the manufacturing conditions used and the chemically acidic environment formed with the degradation of PLGA matrices. The scientific literature
20 contains a large number of descriptions of stability problems in the manufacture of microspheres of PLGA owing to exposure to organic solvents. As an example of the acidic environment which is formed upon the degradation of PLGA matrices, it has recently been shown that the pH
25 value in a PLGA microsphere having a diameter of about 40 μm falls to 1.5, which is fully sufficient to denature, or otherwise damage, many therapeutically usable proteins (Fu et al, Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA)
30 Microspheres, Pharmaceutical Research, Vol. 17, No. 1, 2000, 100-106). Should the microspheres have a greater diameter, the pH value can be expected to fall further owing to the fact that the acidic degradation products then get more difficult to diffuse away and the
35 autocatalytic reaction is intensified.

The technique which is currently most commonly

used to encapsulate water-soluble substances, such as proteins and peptides, is the use of multiple emulsion systems. The drug substance is dissolved in an aqueous or buffer solution and subsequently mixed with an organic solvent, immiscible with water, containing the dissolved polymer. An emulsion is formed which has the aqueous phase as the inner phase. Different types of emulsifiers and vigorous mixing are often used to create this first emulsion. This emulsion is then transferred, under agitation, to another liquid, usually water, containing another polymer, for example polyvinyl alcohol, which produces a water/oil/water triple emulsion. The microspheres are next hardened in some way. The most common way is to utilize an organic solvent having a low boiling point, typically dichloromethane, and to distil off the solvent. If the organic solvent is not fully immiscible with water, a continuous extraction procedure can be used by adding more water to the triple emulsion. A number of variations of this general procedure are also described in the literature. In certain cases, the primary emulsion is mixed with a non-aqueous phase, for example silicone oil. Solid drug materials can also be used instead of dissolved ones.

PLGA microspheres containing proteins are described in WO-A1-9013780, in which the main feature is the use of very low temperatures during the production of the microspheres for the purpose of preserving high biological activity in the proteins. The activity for encapsulated superoxide dismutation is measured, but only on the part which has been released from the particles. This method has been used to produce PLGA microspheres containing human growth hormone in WO-A1-9412158, wherein human growth hormone is dispersed in methylene chloride containing PLGA, the obtained dispersion is sprayed into a container of frozen ethanol beneath a layer of liquid nitrogen in order to freeze the fine droplets and said

droplets are allowed to settle in the nitrogen on the ethanol. The ethanol is subsequently thawed and the microspheres start to sink in the ethanol, where the methylene chloride is extracted in the ethanol and the microspheres are hardened. Using this methodology, the protein stability can be better retained than in the majority of other processes for enclosing proteins in PLGA microspheres, and a product has also recently been approved by the regulatory authorities in the USA. However, this still remains to be clearly demonstrated for other proteins and the problem remains of exposing the enclosed biologically active substance to a very low pH during the degradation of the PLGA matrix.

In the aforementioned methods based on encapsulation with PLGA, the active substances are still exposed to an organic solvent and this, generally speaking, is harmful to the stability of a protein. Moreover, the discussed emulsion processes are complicated and probably problematical in any attempt to scale up to an industrial scale. Furthermore, many of the organic solvents which are utilized in many of these processes are associated with environmental problems and their high affinity for the PLGA polymer makes their removal difficult.

A number of attempts to solve the above-described problems caused by exposure of the biologically active substance to a chemically acidic environment during the biodegradation of the microsphere matrix and organic solvents in the manufacturing process have been described. In order to avoid an acidic environment during the degradation, attempts have been made to replace PLGA as the matrix for the microspheres by a polymer which produces chemically neutral degradation products, and in order to avoid exposing the biologically active substance to organic solvents, either it has been attempted to manufacture the microspheres in advance and, only once

they have been processed and dried, to load them with the biologically active substance, or attempts have been made to exclude or limit the organic solvent during manufacture of the microspheres.

5 By way of example, highly branched starch of relatively low molecular weight (maltodextrin, average molecular weight about 5 000 Da) has been covalently modified with acryl groups for conversion of this starch into a form which can be solidified into microspheres and
10 the obtained polyacryl starch has been converted into particulate form by radical polymerization in an emulsion with toluene/chloroform (4:1) as the outer phase (Characterization of Polyacryl Starch Microparticles as Carriers for Proteins and Drugs, Artursson et al, J Pharm
15 Sci, 73, 1507-1513, 1984). Proteins were able to be entrapped in these microspheres, but the manufacturing conditions expose the biologically active substance to both organic solvents and high shearing forces in the manufacture of the emulsion. The obtained microspheres are
20 dissolved enzymatically and the pH can be expected to be kept neutral. The obtained microspheres are not suitable for parenteral administrations, especially repeated parenteral administration, for a number of reasons. Most important of all is the incomplete and very slow
25 biodegradability of both the starch matrix (Biodegradable Microspheres IV. Factors Affecting the Distribution and Degradation of Polyacryl Starch Microparticles, Laakso et al, J Pharm Sci 75, 962-967, 1986) and the synthetic polymer chain which cross-links the starch molecules.
30 Moreover, these microspheres are far too small, <2 µm in diameter, to be suitable for injection in the tissues for sustained release, since tissue macrophages can easily phagocytize them. Attempts to raise the degradation rate and the degree of degradation by introducing a potentially
35 biodegradable ester group in order to bond the acryl groups to the highly branched starch failed to produce the

intended result and even these polyacryl starch microspheres were biodegraded far too slowly and incompletely over reasonable periods of time (BIODEGRADABLE MICROSPHERES: Some Properties of Polyacryl Starch Microparticles Prepared from Acrylic acid Esterified Starch, Laakso and Sjöholm, 1987 (76), pp. 935-939, J Pharm Sci.)

Microspheres of polyacryl dextran have been manufactured in two-phase aqueous systems (Stenekes et al, The Preparation of Dextran Microspheres in an All-Aqueous System: Effect of the Formulation Parameters on Particle Characteristics, Pharmaceutical Research, Vol. 15, No. 4, 1998, 557-561, and Franssen and Hennink, A novel preparation method for polymeric microparticles without using organic solvents, Int J Pharm 168, 1-7, 1998). With this mode of procedure, the biologically active substance is prevented from being exposed to organic solvents but, for the rest, the microspheres acquire properties equivalent to the properties described for the polyacryl starch microspheres above, which makes them unsuitable for repeated parenteral administrations. Bearing in mind that man does not have specific dextran-degrading enzymes, the degradation rate should be even lower than for polyacryl starch microspheres. The use of dextran is also associated with a certain risk of serious allergic reactions.

Manufacture of starch microspheres with the use of non-chemically-modified starch using an oil as the outer phase has been described (US 4,713,249; Schröder, U., Crystallized carbohydrate spheres for slow release and targeting, Methods Enzymol, 1985 (112), 116-128; Schröder, U., Crystallized carbohydrate spheres as a slow release matrix for biologically active substances, Bio-materials 5:100-104, 1984). The microspheres are solidified in these cases by precipitation in acetone, which leads both to the exposure of the biologically active substance to an organic solvent and to the non-utilization, during the

manufacturing process, of the natural tendency of the starch to solidify through physical cross-linking. This leads, in turn, to microspheres having inherent instability, since the starch, after resuspension in water and upon exposure to body fluids, will endeavour to form such cross-links. In order for a water-in-oil emulsion to be obtained, high shear forces are required and the microspheres which are formed are far too small to be suitable for parenteral sustained release.

EP 213303 A2 describes the production of microspheres of, inter alia, chemically unmodified starch in two-phase aqueous systems, utilizing the natural capacity of the starch to solidify through the formation of physical cross-links, and the immobilization of a substance in these microspheres for the purpose of avoiding exposure of the biologically active substance to organic solvents. The described methodology, in combination with the starch quality which is defined, does not give rise to fully biodegradable particles. Neither are the obtained particles suitable for injection, particularly for repeated injections over a longer period, since the described starch quality contains far too high quantities of foreign vegetable protein. In contrast to what is taught by this patent, it has now also surprisingly been found that significantly better yield and higher loading of the biologically active molecule can be obtained if significantly higher concentrations of the polymers are used than is required to form the two-phase aqueous system and that this also leads to advantages in terms of the conditions for obtaining stable, non-aggregated microspheres and their size distribution. The temperature treatments which are described cannot be used for sensitive macromolecules and the same applies to the processing which comprises drying with either ethanol or acetone.

Alternative methods for the manufacture of

microspheres in two-phase aqueous systems have been described. In US 5 981 719, microparticles are made by mixing the biologically active macromolecule with a polymer at a pH close to the isoelectric point of the macromolecule and stabilizing the microspheres through the supply of energy, preferably heat. The lowest share of macromolecule, i.e. the biologically active substance, in the preparation is 40%, which for most applications is too high and leads to great uncertainty in the injected quantity of active substance, since the dose of microparticles becomes far too low. Even though the manufacturing method is described as mild and capable of retaining the biological activity of the entrapped biologically active substance, the microparticles are stabilized by heating and, in the examples given, heating is effected to at least 58°C for 30 min. and, in many cases, to 70-90°C for an equivalent period, which cannot be expected to be tolerated by sensitive proteins, the biological activity of which is dependent on a three-dimensional structure, and even where the protein has apparently withstood the manufacturing process, there is still a risk of small, but nonetheless not insignificant changes in the conformation of the protein. As the outer phase, a combination of two polymers is always used, generally polyvinyl pyrrolidone and PEG, which complicates the manufacturing process in that both these substances must be washed away from the microspheres in a reproducible and reliable manner. The formed microparticles are too small (in the examples, values below 0.1 μm in diameter are quoted) to be suitable for parenteral sustained release after, for example, subcutaneous injection, since macrophages, which are cells which specialize in phagocytizing particles and which are present in the tissues, are easily capable of phagocytizing microspheres up to 5-10, possibly 20 μm , and the phagocytized particles are localized intracellularly

in the lysosomes, where both the particles and the biologically active substance are degraded, whereupon the therapeutic effect is lost. The very small particle size also makes the processing of the microspheres more complicated, since desirable methods, such as filtration, cannot be used. The equivalent applies to US 5 849 884.

US 5 578 709 and EP 0 688 429 B1 describe the use of two-phase aqueous systems for the manufacture of macromolecular microparticle solutions and chemical or thermal cross-linking of the dehydrated macromolecules to form microparticles. It is entirely undesirable to chemically cross-link the biologically active macromolecule, either with itself or with the microparticle matrix, since chemical modifications of this kind have a number of serious drawbacks, such as reduction of the bioactivity of a sensitive protein and risk of induction of an immune response to the new antigenic determinants of the protein, giving rise to the need for extensive toxicological studies to investigate the safety of the product. Microparticles which are made through chemical cross-linking with glutaraldehyde are previously known and are considered generally unsuitable for repeated administrations parenterally to humans. The microparticles which are described in US 5 578 709 suffer in general terms from the same drawbacks as are described for US 5 981 719, with unsuitable manufacturing conditions for sensitive proteins, either through their exposure to chemical modification or to harmful temperatures, and a microparticle size distribution which is too narrow for parenteral, sustained release and which complicates post-manufacture processing of the microspheres.

WO 97/14408 describes the use of air-suspension technology for producing microparticles for sustained release after parenteral administration, without the biologically active substance being exposed to organic solvents. However, the publication provides no guidance

towards the process according to the invention or towards the novel microparticles which can thereby be obtained.

In US 5 470 582, a microsphere consisting of PLGA and containing a macromolecule is produced by a two-stage process, in which the microsphere as such is first manufactured using organic solvents and then loaded with the macromolecule at a later stage in which the organic solvent has already been removed. This procedure leads to far too low a content of the biologically active substance, generally 1-2%, and to a very large fraction being released immediately after injection, which very often is entirely unsuitable. This far too rapid initial release is already very high given a 1% load and becomes even more pronounced when the active substance content in the microspheres is higher. Upon the degradation of the PLGA matrix, the pH falls to levels which are generally not acceptable for sensitive macromolecules.

That starch is, in theory, a very suitable, perhaps even ideal, matrix material for microparticles has been known for a long time, since starch does not need to be dissolved in organic solvents and has a natural tendency to solidify and since there are enzymes within the body which can break down the starch into endogenic and neutral substances, ultimately glucose, and since starch, presumably owing to the similarity with endogenic glycogen, has been shown to be non-immunogenic. Despite intense efforts, starch having properties which enable manufacture of microparticles suitable for parenteral use and conditions which enable manufacture of fully biodegradable microparticles under mild conditions, which allow sensitive, biologically active substances, such as proteins, to become entrapped, has not been previously described.

Starch granules naturally contain impurities, such as starch proteins, which makes them unsuitable for injection parenterally. In the event of unintentional

depositing of insufficiently purified starch, such as can occur in operations where many types of operating gloves are powdered with stabilized starch granules, very serious secondary effects can arise. Neither are starch granules
5 intrinsically suitable for repeated parenteral administrations, for the reason that they are not fully biodegradable within acceptable time spans.

Starch microspheres made of acid-hydrolyzed and purified starch have been used for parenteral
10 administration to humans. The microspheres were made by chemical cross-linking with epichlorohydrin under strongly alkaline conditions. The chemical modification which was then acquired by the starch leads to reduced biodegradability, so that the microspheres can be fully
15 dissolved by endogenic enzymes, such as α -amylase, but not converted fully into glucose as the end product. Neither the manufacturing method nor the obtained microspheres are suitable for the immobilization of sensitive proteins, nor is such acid-hydrolyzed starch,
20 which is essentially based on hydrolyzed amylose, suitable for producing either fully biodegradable starch microspheres or starch microspheres containing a high load of a biologically active substance, such as a protein.

Hydroxyethyl starch (HES) is administered
25 parenterally to humans in high doses as a plasma substitute. HES is produced by starch granules from starch consisting broadly exclusively of highly branched amylopectin, so-called "waxy maize", being acid-hydrolyzed in order to reduce the molecular weight distribution and
30 being subsequently hydroxyethylated under alkaline conditions and acid-hydrolyzed once more to achieve an average molecular weight of around 200,000 Da. After this, filtration, extraction with acetone and spray-drying are carried out. The purpose of the hydroxyethylation is to
35 prolong the duration of the effect, since non-modified amylopectin is very rapidly degraded by α -amylase and its

residence time in the circulation is ca. 10 minutes. HES is not suitable for the production of fully biodegradable microspheres containing a biologically active substance, since the chemical modification leads to a considerable fall in the speed and completeness of the biodegradation and results in the elimination of the natural tendency of the starch to solidify through the formation of non-covalent cross-linkings. Moreover, highly concentrated solutions of HES become far too viscous to be usable for the production of microparticles. The use of HES in these high doses shows that parenterally usable starch can be manufactured, even though HES is not usable for the manufacture of microspheres without chemical cross-linking or precipitation with organic solvents.

WO 99/00425 describes the use of heat-resistant proteolytic enzymes with wide pH-optimum to purge starch granules of surface-associated proteins. The obtained granules are not suitable for parenteral administration, since they still contain the starch proteins which are present within the granules and there is a risk that residues of the added proteolytic enzymes will be left in the granules. Neither are the granules suitable for the manufacture of parenterally administrable starch microspheres in two-phase aqueous systems, since they have the wrong molecular weight distribution to be able to be used in high enough concentration, even after being dissolved, and, where microspheres can be obtained, they are probably not fully biodegradable.

The use of shearing to modify the molecular weight distribution of starch, for the purpose of producing better starch for the production of tablets, is described in US 5,455,342 and WO 93/21008. The starch which is obtained is not suitable for parenteral administration owing to the high content of starch proteins, which might be present in denatured form after the shearing, and neither is the obtained starch suitable for producing

biodegradable starch microspheres for parenteral administration or for use in two-phase aqueous systems for the production of such starch microspheres. Shearing has also been used to manufacture hydrocyethylstarch, as is disclosed in WO 96/10042. However, for similar reasons such hydrocyethylstarch is not either suitable for parenteral administration or for the production of microspheres as referred to above.

A process for the production of parenterally administrable starch preparations having the following features would therefore be extremely desirable:

- a process which makes it possible to entrap sensitive, biologically active substances in microparticles with retention of their biological activity;
- a process by means of which biologically active substances can be entrapped under conditions which do not expose them to organic solvents, high temperatures or high shear forces and which allows them to retain their biological activity;
- a process which permits high loading of a parenterally administrable preparation with even sensitive, biologically active substances;
- a process by means of which a substantially fully biodegradable and biocompatible preparation can be produced, which is suitable for injecting parenterally and upon whose degradation chemically neutral endogenic substances are formed;
- a process by means of which a parenterally injectable preparation having a size exceeding 20 μm and, preferably exceeding 30 μm , is produced for the purpose of avoiding phagocytosis of tissue macrophages and which simplifies processing of the same during manufacture;
- a process for the production of microparticles containing a biologically active substance, which microparticles can be used as intermediate product in

- the production of a preparation for controlled, sustained or delayed release and which permit rigorous quality control of the chemical stability and biological activity of the entrapped biological substance;
- a process which utilizes a parenterally acceptable starch which is suitable for the production of substantially fully biodegradable starch microparticles;
 - a substantially fully biodegradable and biocompatible microparticulate preparation which is suitable for injecting parenterally and upon whose degradation chemically neutral endogenic substances are formed;
 - a microparticulate preparation containing a biologically active substance and having a particle size distribution which is suitable for coating by means of air suspension technology and having sufficient mechanical strength for this purpose.

Objects such as these and other objects are achieved by means of the invention defined below.

DESCRIPTION OF THE INVENTION

According to a first aspect of present invention, it relates to a process for production of microparticles. More specifically it relates to production of microparticles which contain a biologically active substance and which are intended for parenteral administration of the said substance to a mammal, especially a human. The said parenteral administration primarily means that the microparticles are intended for injection.

Since the microparticles are primarily intended for injection, it is a question especially of manufacturing particles with an average diameter within the range of 10-200 μm , generally 20-100 μm and in particular 20-80 μm .

The expression "microparticles" is used in connection

with the invention as a general designation for particles of a certain size known in the art. One type of microparticles is that of microspheres which have in the main a spherical shape, although the term microparticle
5 may generally include deviations from such an ideal spherical shape. The term microcapsule known in the art is also covered by the expression microparticle in accordance with the known art.

The process according to the present invention more
10 specifically comprises:

- a) preparing of an aqueous starch solution containing starch, which has an amylopectin content in excess of 85 percent by weight, in which the molecular weight of said amylopectin has been reduced such that at least 80 percent
15 by weight of the material lies within the range of 10-10 000 kDa, and which has an amino acid nitrogen content of less than 50 µg per g dry weight of starch, the starch concentration of the solution being at least 20 percent by weight,
- 20 b) combining the biologically active substance with the starch solution under conditions such that a composition is formed in the form of a solution, emulsion or suspension of said substance in the starch solution,
- c) mixing the composition obtained in step b) with an
25 aqueous solution of a polymer having the ability to form a two-phase aqueous system, so that an emulsion of starch droplets is formed which contain the biologically active substance as an inner phase in an outer phase of said polymer solution,
- 30 d) causing or allowing the starch droplets obtained in step c) to gel into starch particles through the natural propensity of the starch to solidify,
- e) drying the starch particles, and
- f) optionally applying a release-controlling shell of a
35 biocompatible and biodegradable polymer, preferably by an air suspension method, to the dried starch particles.

An important aspect of this process is, in other words, the use of a certain type of starch as microparticle matrix. One starch that is especially suitable, and a process for the production thereof, are described in the Swedish patent application No. 0003616-0. In this case the molecular weight reduction is accomplished by shearing. Another useful starch is disclosed in a PCT application copending to the present application and entitled STARCH.

10 In last-mentioned case the molecular weight reduction is accomplished by acid hydrolysis.

Details about the starch may in other words be obtained from said patent applications, the contents of which are thus in this respect introduced into the present text by way of reference.

Some further important features of such a starch will, however, be described below. In order that fully biodegradable microparticles with high active substance yield shall be formed in a two-phase aqueous system and in order that the obtained starch microparticles shall have the properties to be described below, the starch must generally predominantly consist of highly branched starch, which, in the natural state in the starch granule, is referred to as amylopectin. It should also have a molecular weight distribution which makes it possible to achieve desired concentrations and gelation rates.

It may be added, in this context, that the term "biodegradable" means that the microparticles, after parenteral administration, are dissolved in the body to form endogenic substances, ultimately, for example, glucose. The biodegradability can be determined or examined through incubation with a suitable enzyme, for example alpha-amylase, in vitro. It is in this case appropriate to add the enzyme a number of times during the incubation period, so as thereby to ensure that there is active enzyme permanently present in the incubation

mixture. The biodegradability can also be examined through parenteral injection of the microparticles, for example subcutaneously or intramuscularly, and histological examination of the tissue as a function of time.

5 Biodegradable starch microparticles disappear normally from the tissue within a few weeks and generally within one week. In those cases in which the starch microparticles are coated with a release-controlling shell, for example coated, it is generally this shell
10 which determines the biodegradability rate, which then, in turn, determines when alpha-amylase becomes available to the starch matrix.

 The biocompatibility can also be examined through parenteral administration of the microparticles, for
15 example subcutaneously or intramuscularly, and histological evaluation of the tissue, it being important to bear in mind that the biologically active substance, which often is a protein, has in itself the capacity to induce, for example, an immunodefence if administered in
20 another species. For example, a large number of recombinantly produced human proteins can give rise to an immune response in test animals.

 The starch must further have a purity which is acceptable for the manufacture of a parenterally
25 administrable preparation. It must also be able to form sufficiently stable solutions in sufficiently high concentration to enable the biologically active substance to be mixed in under conditions allowing the retention of the bioactivity of the substance, at the same time as it
30 must spontaneously be able to be solidified in a controlled manner in order to achieve stable, yet at the same time biodegradable, microparticles. High concentration of the starch is also important to prevent the biologically active substance from being distributed
35 out to an unacceptable extent to the outer phase or to the interface between the inner and the outer phases.

A number of preferred embodiments with regard to the character of the starch are as follows.

The starch preferably has a purity of at most 20 μg , more preferably at most 10 μg , and most preferably at most 5 μg , amino acid nitrogen per g dry weight of starch.

The molecular weight of the abovementioned amylopectin is preferably reduced, such that at least 80% by weight of the material lies within the range of 100-4 000 kDa, more preferably 200-1 000 kDa, and most preferably 300-600 kDa.

In addition, the starch preferably has an amylopectin content with the reduced molecular weight in question exceeding 95% by weight, more preferably exceeding 98% by weight. It can also, of course, consist of 100% by weight of such amylopectin.

According to another preferred embodiment, the starch is of such a type that it can be dissolved in water in a concentration exceeding 25% by weight. This means, in general, a capacity to dissolve in water according to a technique which is known per se, i.e. usually dissolution at elevated temperature, for example up to approximately 80°C.

According to a further preferred embodiment, the starch is substantially lacking in covalently bonded extra chemical groups of the type which are found in hydroxyethyl starch. By this is meant, in general, that the starch essentially only contains groups of the type which are found in natural starch and have not been in any way modified, such as in hydroxyethyl starch, for example.

Another preferred embodiment involves the starch having an endotoxin content of less than 25 EU/g.

A further preferred embodiment involves the starch containing less than 100 microorganisms per gram, often even less than 10 microorganisms per gram.

The starch can further be defined as being substantially purified from surface-localized proteins,

lipids and endotoxins by means of washing with aqueous alkali solution, reduced in molecular weight by means of shearing, and purified from internal proteins by means of ion exchange chromatography, preferably anion exchange chromatography.

As far as the purity in all these contexts is concerned, it is in general the case that expressions of the type "essentially" or "substantially" generally mean to a minimum of 90%, for example 95%, 99% or 99.9%.

That amylopectin constitutes the main component part in the starch used means in general terms that its share is 60-100% by weight, calculated on the basis of dry weight of starch.

In certain cases, it can here be favourable to use a lesser share, for example 2-15% by weight, of short-chain amylose to modify the gelation rate in step d). The average molecular weight of the said amylose lies preferably within the range of 2.5-70 kDa, especially 5-45 kDa. Other details regarding short-chain amylose can be obtained from US patent specification 3,881,991.

In the formation of the starch solution in step a), heating according to a technique which is known per se is in general used to dissolve the starch. An especially preferred embodiment simultaneously involves the starch being dissolved under autoclaving, it also preferably being sterilized. This autoclaving is realized in aqueous solutions, for example water for injection or suitable buffer.

If the biologically active substance is a sensitive protein or another temperature-sensitive substance, the starch solution must cool to an appropriate temperature before being combined with the substance in question. What temperature is appropriate is determined firstly by the thermal stability of the biologically active substance, but in purely general terms a

temperature of less than ca. 60°C, preferably less than 55°C, is appropriate.

According to a preferred embodiment, the active substance is therefore combined with the starch solution
5 at a temperature of at most 60°C, more preferably at most 55°C, and most preferably within the range of 20-45°C, especially 30-37°C.

For the mixing operation in step b), furthermore, a weight ratio of starch:biologically active substance
10 within the range of 3:1 to 10 000:1, preferably 3:1 to 100:1, is expediently used.

It is also the case for the mixing operation that the active substance is mixed with the starch solution before a two-phase aqueous system is formed in step c).
15 The active substance can be in dissolved form, for example in a buffer solution, or in solid, amorphous or crystalline form, and at a suitable temperature, which is generally between room temperature (20°C) and 45°C, preferably at most 37°C. It is possible to add the starch
20 solution to the biologically active substance, or vice versa. Since the biologically active substances suitable for use in this system, for example proteins, are generally macromolecules, it is possible, when mixing a solution of a dissolved macromolecule with starch, for an
25 emulsion to form, in which the macromolecule generally represents the inner phase, or a precipitate. This is entirely acceptable, provided that the biologically active substance retains or does not appreciably lose its bioactivity. A homogeneous solution, emulsion or
30 suspension is then created by agitation, which can be carried out using a suitable technique. Such a technique is well known within the field, examples which might be quoted being magnetic agitation, propeller agitation or the use of one or more static mixers. An especially
35 preferred embodiment of the invention is represented in this case by the use of propeller agitation.

In the production of the starch microparticles according to the present invention, the concentration of starch in the solution which is to be converted to solid form and in which the biologically active substance is to be incorporated should be at least 20% by weight to enable the formation of starch microparticles having good properties. Exactly what starch concentration works best in each individual case can be titrated out in a simple manner for each individual biologically active substance, where the load in the microparticles is that which is required in the individual case. In this context, it should be noted that the biologically active substance to be incorporated in the microparticles can affect the two-phase system and the gelation properties of the starch, which also means that customary preparatory trials are conducted for the purpose of determining the optimal conditions in the individual case. Trials generally show that the starch concentration should advantageously be at least 30% by weight and in certain specific cases at least 40% by weight. As the highest limit, 50% by weight is usually applicable, especially at most 45% by weight. It is not normally possible to obtain these high starch concentrations without the use of molecular-weight-reduced, highly branched starch.

Regarding the polymer used in step c) for the purpose of forming a two-phase aqueous system, information is published, within precisely this technical field, on a large number of polymers with the capacity to form two-phase systems with starch as the inner phase. All such polymers must be considered to lie within the scope of the present invention. An especially suitable polymer in this context, however, is polyethylene glycol. This polyethylene glycol preferably has an average molecular weight of 5-35 kDa, more preferably 15-25 kDa and especially about 20 kDa.

The polymer is dissolved in suitable concentration

in water or aqueous solution, which expression also includes buffer solution, and is temperature-adjusted to a suitable temperature. This temperature lies preferably within the range of 4-50°C, more preferably 10-40°C and most preferably 10-37°C. The concentration of the polymer in the aqueous solution is at least 20% by weight and preferably at least 30% by weight, and more expediently at most 45% by weight. An especially preferred range is 30-40% by weight.

10 The mixing operation in step c) can be executed in many different ways, for example through the use of propeller agitation or at least one static mixer. The mixing is normally carried out within the temperature range of 4-50°C, preferably 20-40°C, often about 37°C. In
15 a batch process, the starch solution can be added to the polymer solution or vice versa. Where static mixers or blenders are utilized, the operation is expediently executed by the two solutions being pumped in two separate pipelines into a common pipeline containing the blenders.

20 The emulsion can be formed using low shearing forces, since there is no high surface tension present between the phases in water/water emulsions, in contrast to oil/water or water/oil emulsions, and in this case it is primarily the viscosity of the starch solution which
25 has to be overcome for the droplets to achieve a certain size distribution. In most cases, magnetic or propeller agitation is sufficient. On a larger scale, for example when the quantity of microparticles to be produced exceeds 50 g, it is expedient to use so-called baffles to obtain
30 even more effective agitation in the container which is used. An alternative way of forming the water/water emulsion is to use at least one static mixer, the starch solution expediently being pumped at regulated speed in a pipe in which the static mixers have been placed. The
35 pumping can be effected with any type of suitable pump, provided that it gives an even flow rate under these

conditions, does not expose the mixture to unnecessarily high shear forces and is acceptable for the manufacture of parenteral preparations in terms of purity and non-leakage of unwanted substances. In those cases, too, in which
5 static mixers are used to create the emulsion, it is generally advantageous to have the solidification into microparticles take place in a vessel with suitable agitation.

A preferred embodiment of the process according to
10 the invention means that in step c) the polymer solution is added to the composition in at least two stages, in which an admixture is effected after the emulsion has been created or has begun to be created.

It is also within the scope of the present
15 invention, of course, to add the polymer solutions in many stages and to change, for example, the average molecular weight and/or concentration of the polymer used, for example in order to increase the starch concentration in the inner phase where this is desirable.

The mixing operation in step c) is also
20 expediently executed under such conditions that the starch droplets formed have the size required for the microparticles, i.e. preferably a mean diameter, in the dry state, within the range of 10-200 μm , preferably
25 20-100 μm , more preferably 20-80 μm .

In the production of the microparticles according to the present invention it is essential that the solidification occurs through the natural tendency or capacity of the starch to gel and not, for example,
30 through precipitation with organic solvents, such as acetone. The latter procedure may lead to the biologically active substance being exposed to organic solvent, which in many cases is unacceptable, and to an absence of the natural formation of the physical cross-
35 linkages that are required in order to obtain stable microparticles in a controlled manner.

In connection with the solidification of the microparticles, it is important that this should take place under conditions which are mild for the incorporated biologically active substance(s). In other words, it is primarily a question of using a temperature which is not harmful to the current substance. In this context, it has surprisingly been shown that the criteria for this and for the formation of stable microparticles with suitable size distribution can more easily be met if, during the solidification, more than one temperature or temperature level is used. It is especially advantageous if the solidification process in the two-phase system is initiated at a lower temperature than the temperature which is used in the end phase of the solidification. A preferred embodiment means that the solidification is initiated within the range of 1-20°C, preferably 1-10°C, especially around 4°C, and is concluded within the range of 20-55°C, preferably 25-40°C, especially around 37°C.

Confirmation that the chosen conditions are correct or appropriate can be obtained by establishing that the starch microparticles have a desired size distribution, are stable during the subsequent washing and drying operations and are dissolved substantially by fully enzymatic means in vitro and/or that the incorporated substance has been encapsulated effectively and has retained bioactivity. The last-mentioned is usually examined using chromatographic methods or using other methods established within the art, in vitro or in vivo, after the microparticles have been enzymatically dissolved under mild conditions, and is an important element in ensuring a robust and reliable manufacturing process for sensitive, biologically active substances. It is a great advantage for the microparticles to be able to be fully dissolved under mild conditions, since this minimizes the risks of preparation-induced artifacts, which are usually found when, for example, organic solvents are required to

dissolve the microparticles, which is the case, for example, when these consist of a PLGA matrix.

The formed microparticles are preferably washed in a suitable manner in order to remove the outer phase and any surplus active substance. Such washing is expediently effected by filtration, which is made possible by the good mechanical stability and suitable size distribution of the microparticles. Washing by means of centrifugation, removal of the supernatant and resuspension in the washing medium may often also be appropriate. In each washing process, one or more suitable washing media are used, which generally are buffer-containing aqueous solutions. In this connection, sieving can also be used, if required, in order to adjust the size distribution of the microparticles, for example to eliminate the content of too small microparticles and to ensure that no microparticles above a certain size are present in the finished product.

The microparticles can be dried in any way appropriate, for example by spray-drying, freeze-drying or vacuum-drying. Which drying method is chosen in the individual case often depends on what is most appropriate for the retention of the biological activity for the enclosed biologically active substance. Process considerations also enter into the picture, such as capacity and purity aspects. Freeze-drying is often the preferred drying method, since, correctly designed, it is especially mild with respect to the enclosed biologically active substance. That the incorporated biologically active substance has retained its bioactivity can be established by means of analysis appropriate to the microparticle after the substance has been enzymatically dissolved under mild conditions. Suitable enzymes for use in connection with starch are alpha-amylase and amyloglucosidase, singly or in combination, it being important to establish, where appropriate, that they are

free from possible proteases, which can degrade proteins. The presence of proteases can be detected with methods known within the field and, for example, by mixing the biologically active substance in control trials and
5 determining its integrity in the usual manner after incubation with the intended enzyme mixture under the conditions which will afterwards be used to dissolve the microparticles.

The enzymes used may need to be purified from
10 contaminating proteases, for example, in order to avoid artifactual degradation of sensitive substances, such as recombinant proteins, for example, incorporated into the microparticles. This can be done using techniques known within the field, for example by chromatography with α_2 -
15 macroglobulin bonded to a suitable chromatography material.

In order to modify the release properties for the microparticles, a release-controlling shell, or coating, made from a biocompatible and biodegradable polymer might
20 also be applied. Examples of suitable polymers in this context are found in the prior art, for example EP 535 937, and polymers of lactic acid and glycolic acid (PLGA) can especially be mentioned. The shell in question is preferably applied using air suspension technology. An
25 especially suitable technique of this kind is described in WO97/14408 and details in this regard can thus be obtained from this publication, the content of which is included in the text by reference. The starch microparticles which are obtained by means of the process according to the present
30 invention are extremely well suited to coating or coating by means of the said air suspension technology, and the coated microparticles obtained are especially well suited to parenteral administration.

When the produced microparticles are used, either
35 they are coated with a release-controlling outer shell or not, and the dry microparticles are suspended in a

suitable medium, specifically to permit injection. Such media and processes in these regards are well known within the field and will not need here to be described in further detail. The actual injection can be given through
5 a suitable needle or with a needle-free injector. It is also possible to inject the microparticles using a dry powder injector, without prior resuspension in an injection medium.

Apart from the advantages which have been
10 discussed above, the process according to the invention has the advantage that the yield of the biologically active substance is generally high, that it is possible to obtain a very high active substance content in the microparticles whilst retaining the bioactivity of the
15 substance, that the obtained microparticles have the correct size distribution for use for parenteral, controlled (for example delayed or sustained) release, since they are too large to be phagocytized by macrophages and small enough to be injectable through small needles,
20 for example 23G-25G, and that endogenic and neutral degradation products are formed upon degradation of the microparticles, by which means the active substance, for example, can be prevented from being exposed to an excessively low pH value. Moreover, the process itself is
25 especially well suited to rigorous quality control.

The process according to the invention is especially interesting in connection with proteins, peptides, polypeptides, polynucleotides and polysaccharides or, in general, other drugs or
30 biologically active substances which are sensitive to or unstable in, for example, organic solvents, primarily water-soluble substances. Recombinantly produced proteins are a very interesting group of biologically active substances. Generally speaking, however, the invention is
35 not limited to the presence of such substances, since the inventive concept is applicable to any biologically active

substance which can be used for parenteral administration. Apart from in connection with sensitivity or instability problems, the invention can thus also be of special interest in such cases where it would otherwise be difficult to remove solvent or where toxicological or other environmental problems might arise.

Classes of biologically active substances to be used are e.g. recombinant proteins, glycosylated recombinant proteins, pegylated recombinant proteins, growth factors, cytokines, blood coagulation factors, monoclonal antibodies, LHRH analogues, and vaccines.

Specific examples of substances are growth hormone, erythropoietin and analogues thereof, interferon (α , β , γ), blood coagulation factors V - XIII, protein C, insulin and derivatives thereof, macrophage-colony-stimulating factor, granulocyte-colony-stimulating factor, interleukin, glucagon-like peptide 1 or 2, C-peptide, leptin, tumour necrosis factor and epidermal growth factor.

Usable biologically active substances of the non-protein drug type can be chosen from the following groups:

Antitumour agents, antibiotics, anti-inflammatory agents, antihistamines, sedatives, muscle-relaxants, antiepileptic agents, antidepressants, antiallergic agents, bronchodilators, cardiotonic agents, antiarrhythmic agents, vasodilators, antidiabetics, anticoagulants, haemostatic agents, narcotics and steroids.

According to another aspect of the invention, it also relates to novel microparticles of the type which are obtainable by means of the process according to the invention. The novel microparticles according to the invention are not limited, however, to those which can be produced by means of the said process, but comprise all microparticles of the type in question irrespective of the production methods.

More specifically, these are microparticles suitable for parenteral administration, preferably by way of injection, to a mammal, especially a human, and containing a biologically active substance, which microparticles
5 consist substantially of starch that has an amylopectin content in excess of 85 percent by weight, of which at least 80 percent by weight has an average molecular weight in the range 10-1 000 kDa, which have an amino acid content of less than 50 μ g per dry weight of starch and
10 which lack covalent chemical cross-linking between the starch molecules.

The starch on which the microparticles in question are based is preferably one of the types of starch defined above in connection with the process.

15 According to a preferred embodiment of the microparticles according to the invention, the bioactivity of the biological substance in these is at least 80%, preferably at least 90% of the bioactivity that the substance exhibited before it was incorporated into the
20 starch. The said bioactivity is most preferably largely retained or preserved in the microparticles.

Yet another preferred embodiment of the invention is represented by microparticles which are biodegradable in vitro in the presence of α -amylase and/or
25 amyloglucosidase.

Another embodiment is represented by those that are biodegradable and are eliminated from tissue after subcutaneous or intramuscular administration.

An especially preferred embodiment of the
30 microparticles is represented by particles which have a release-controlling shell of at least one film-forming, biocompatible and biodegradable polymer.

The said polymer is preferably a homopolymer or copolymer made from α -hydroxy acids, the said α -hydroxy
35 acid preferably being lactic acid and/or glycolic acid. Another variant is cyclic dimer of an α -hydroxy acid

which is preferably selected from the group consisting of glycolides and lactides.

Such polymers or dimers (of the PLGA type, for example) are precisely described in the prior art, and
5 further details of these may therefore be obtained therefrom.

Another embodiment is represented by microparticles in which, in addition to said polymer, the shell contains at least one release regulating substance. Such a
10 substance is preferably water soluble or sparingly water soluble. It is preferably selected from lactic acid, oligomers containing lactic acid and glycolic acid.

It may also advantageously be selected from substances comprising polyethylene glycol (PEG) and block
15 copolymers comprising PEG as one of the blocks.

Another interesting embodiment is represented by microparticles which have an outer layer of at least one water soluble substance having the ability to prevent aggregation of the microparticles.

20 A further preferred embodiment of the microparticles is, of course, represented by those microparticles that are obtainable or are produced by means of a process as has been defined above, either in general or in the form of any preferred embodiment of the said process.

25 As regards the determination of the biological activity for the microparticles containing active substance, this must be carried out in a manner appropriate to each individual biological substance. Where the determination is effected in the form of animal
30 trials, a certain quantity of the biologically active substance incorporated in the starch microparticles is injected, possibly after these microparticles have been previously enzymatically dissolved under mild conditions, and the biological response is compared with the response
35 obtained after injection of a corresponding quantity of the same biologically active substance in a suitable

solution. Where the evaluation is made in vitro, for example in test tubes or in cell culture, the biologically active substance is preferably made fully available before the evaluation by the starch microparticles being enzymatically dissolved under mild conditions, after which the activity is determined and compared with the activity for a control solution having the same concentration of the biologically active substance in question. In any event, the evaluation shall include any non-specific effects of the degradation products of the starch microparticles.

The invention will now be explained further with reference to the following non-limiting examples. In these, as in the rest of the text, unless otherwise stated the percentages quoted relate to percentage by weight. Examples 1 to 7 relate to comparative tests, whilst Examples 8 to 13 represent the invention.

EXAMPLES

20

Examples 1a - 1e-b

Control tests: procedure for the production of starch microspheres according to EP 213303 A2. The object of these control tests was to show the state of the art. The starch concentration was generally 5%, and the PEG concentration was 6% (av. mol. wt. 6 kDa). The starch solution (10g) was poured into the PEG solution (5g, temperature-adjusted to 70°C) and stabilized whilst stirring at room temperature overnight. The materials were then resuspended down in 95% ethanol, since it was not possible to filter them. During the various steps, the occurrence of discrete microspheres was observed and, where it was possible, the biodegradability was analyzed in vitro with α -amylase after recovery. Initially attempts were made to recover the microspheres by filtering, but since this was not possible centrifuging

(Sorfvall, SS34, 5 min, 10 000 rpm 20°C) was employed, the supernatant was drawn off and 10 ml of 95% ethanol were added.

5 Example 1a

Production of starch microspheres from potato starch.

The potato starch (Acros organics, Lot No. A013642301) formed a clear solution with very high viscosity even at 5%. After stabilizing overnight, discrete microspheres had not been formed, but rather a type of precipitate. After washing with 95% ethanol, no discrete starch microspheres were found, but a rather hard, viscous lump.

15 Example 1a-b

Production of starch microspheres containing BSA.

Starch microspheres were produced according to example 1a, with the difference that a protein (bovine serum albumin (BSA), 20%, 0.1 ml) was mixed with the starch solution before creation of the two-phase system. After stabilizing overnight, discrete microspheres had not been formed, but rather a type of precipitate, and after washing with 95% ethanol a viscous lump was obtained, but no discrete microspheres.

25

Example 1b

Production of starch microspheres from soluble starch.

The soluble starch (Baker BV - Deventer Holland), Lot No. M27602) gave a somewhat opalescent solution when heated to 95°C. No discrete microspheres had been formed after stirring overnight, but a type of precipitate. After washing with 95% ethanol, no discrete microspheres could be observed, but the starch had been precipitated in the form of small gravel-like particles. After drying, approx. 4 mg of particles were obtained out of a total 500 mg of starch prepared. On incubation with α -amylase in

vitro, approx. 65% of the starch matrix was resistant and did not dissolve.

Example 1b-b

- 5 Incorporation of BSA into starch microspheres produced from soluble starch.

The process according to example 1b was repeated, except that BSA (20%, 0.1 ml) was mixed with the starch solution before creation of the two-phase system. After
10 stabilization overnight, discrete particles had been formed, which were recovered, following which the biodegradability was analyzed in vitro through incubation with α -amylase, with the result that approximately 57% of the matrix was soluble. The protein yield was low and
15 could not be quantified, since the concentration obtained after partial dissolution of the microspheres was lower than the lowest standard in the standard curve for the HPLC method.

20 Example 1c

Production of starch microspheres from oxidized, soluble starch.

The starch (Perfectamyl A3108, Stalex) formed a clear solution after being heated to 95°C. No discrete
25 microspheres had been formed after stabilization overnight and no solid material at all could be found in the specimen.

Example 1c-b

- 30 Incorporation of BSA into starch microspheres produced from soluble starch.

The process according to example 1c was repeated, except that BSA (20%, 0.1 ml) was mixed with the starch solution before creation of the two-phase system. After stabilization, a precipitate was observed, which did not
35 resemble starch, and after washing and drying approx. 2 mg of solid material was obtained.

Example 1d

Production of starch microspheres from native highly branched starch (amylopectin).

5 The native amylopectin starch (Cerestar SF 04201) gave a clear and viscous solution on heating to 95°C. After stirring overnight, no discrete microspheres could be observed, but the specimen was made up of some sort of precipitate. After washing with 95% ethanol, the specimen
10 had become a slimy mass and contained no discrete starch microspheres.

Example 1d-b

15 Incorporation of BSA into starch microspheres produced from native highly branched starch (amylopectin).

 The process according to example 1d was repeated, except that BSA (20%, 0.1 ml) was mixed with the starch solution before creation of the two-phase system. After stabilization, a precipitate was observed, which did not
20 resemble starch, and after washing and drying a viscous lump was obtained.

Example 1e

25 Production of starch microspheres from acid-hydrolyzed and sheared amylopectin.

 The starch was originally composed of acid-hydrolyzed waxy maize (Cerestar 06090) and was also sheared mechanically in order to give a molecular weight distribution that is better suited to the production of
30 starch microspheres in a two-phase aqueous system. After heating to approx. 95°C, a clear solution was obtained. After stirring overnight, no discrete microspheres could be observed but the specimen consisted of a type of precipitate. After washing with 95% ethanol, no discrete
35 microspheres could be observed but the starch had formed small particles.

Example 1e-b

Incorporation of BSA into starch microspheres produced from acid-hydrolyzed and sheared starch (amylopectin).

- 5 The process according to example 1e was repeated, except that BSA (20%, 0.1 ml) was mixed with the starch solution before creation of the two-phase system. After stabilization overnight, no discrete microspheres could be observed. On the other hand an extremely small
10 precipitate could be observed. After recovery, the quantity obtained was so small that no precise determination could be undertaken.

Example 2

- 15 Production of starch microspheres from amylose.

Starch microspheres were produced from amylose (from Serva) with the aim of analyzing their biodegradability in vitro and in vivo. Since amylose gels too rapidly to permit manual production, a machine was used which permits
20 continuous production. The central unit of the machine is a microwave unit that permits rapid heating of the starch to approx. 150°C, followed by cooling to approx. 45°C before mixing with protein solution or buffer solution. The starch solution was prepared in distilled water, since
25 otherwise it turns a brown colour when heated in the microwave unit. The starch was composed of pre-gelatinized amylose (4%) and despite repeated homogenizations a number of lumps remained. The flows were adjusted as follows: starch (5 ml/min), Tris buffer,
30 pH 7.8 (1.2 ml/min) and the PEG solution (2.4 percent by weight PEG with an av. mol. wt. of 300, 000 Da) which also contained 6.9% sodium chloride and 14.3% mannitol. The microparticles were allowed to stabilize at room temperature for some hours and then in a refrigerator
35 overnight. They were recovered by successive washings in a centrifuge: three times with 70% ethanol, three times

with 5 mm phosphate-buffered common salt solution containing 1 mM calcium chloride and 0.02% sodium azide (pH 7.4), and finally three times with 99.5% ethanol. The microparticles were vacuum-dried. Since there were some very small particles in the preparation, attempts were made to remove these by threefold sedimentations in 99.5% ethanol, which did not result in complete removal of these. A total of 9.5 g of microparticles were obtained and after sedimentation 8.5 g remained.

The particle size distribution was determined with a Malvern Mastersizer and was found to be broad, with the smallest microspheres about 5 μ m and the largest over 160 μ m. The mean diameter calculated from the volume was 25 μ m. Approx. 30-40% of the starch matrix was dissolved when the microspheres were incubated with α -amylase at 37°C in vitro for two weeks.

This comparative example shows the difficulties involved in producing microspheres from amylose, since it is difficult to make up into homogeneous solutions, requires very high temperatures in order to dissolve and is susceptible to degradation when subjected to these high temperatures, and gels very quickly. The example also shows that the resulting microspheres have far too broad a size distribution both immediately after production and after attempts to narrow the size distribution, and far too high a content of microspheres with a size of less than 10 μ m to be well suited to sustained release after subcutaneous or intramuscular injection. The example also shows that the biodegradability, analyzed in vitro, is incomplete over the period of time analyzed.

Example 3

Production of starch microspheres containing β -lactoglobulin.

Starch microspheres were produced from amylose (Serva) in order to analyze the effectiveness of

immobilization of a model protein, β -lactoglobulin. Since this amylose gels too rapidly to permit entirely manual production, a machine was used with a microwave unit that permits rapid heating of the starch to approximately 5 150°C, followed by cooling to around 45°C before mixing with protein solution or buffer solution. The starch solution (10%) was prepared in distilled water and the flow was set to 5 g/minute. The starch solution (2.5 ml) was collected in a plastic beaker and as the temperature 10 fell to 50-70°C the protein solution (0.6 ml, 8.3% in buffer) was added thereto under magnetic stirring. Broadly speaking, immediately thereafter the first PEG solution (10%, av. mol. wt. 20, 000 Da, 3.0 ml) was added to the starch solution under stirring, and after one 15 minute's stirring the second PEG solution (40%, av. mol. wt 20, 000 Da, 10 ml) was added to the emulsion, which was left to stabilize at room temperature until the next day. The microspheres formed were recovered by two different methods in order to demonstrate their capacity to retain 20 an adequate protein loading. The first washing method consisted of centrifuge washings with buffer solutions and resulted in largely all protein leaching out of the starch microspheres. In the second method of recovery, isopropyl alcohol was also used in order to increase the 25 lactoglobulin loading in the microspheres. In this method washing was first performed three times with 70% isopropyl alcohol, then once with 5 mM of phosphate-buffered common salt solution containing 1 mM of calcium chloride and 0.02% sodium azide, then once again with the same buffer 30 before being left to stand in the buffer for one hour with agitation, thereafter 5 times with buffer and finally 3 times with 100% isopropyl alcohol. The microspheres were then vacuum-dried. The protein loading using the isopropyl alcohol wash was 3.6%, which corresponds to a 35 theoretical yield of 18%.

Among other things, the example points to significant practical difficulties in producing microspheres containing protein from amylose, since the starch solution must be subjected to very high temperatures for it to be dissolved completely, since the starch readily undergoes chemical changes at these high temperatures and gels very rapidly after cooling to temperatures that are reasonably low in order to allow the starch solution to be mixed with a sensitive protein. Production is further complicated by the need to use two different solutions of PEG, in order to permit the formation of microspheres and entrapment of the protein therein. A further serious disadvantage is the need to use isopropyl alcohol in the recovery of the microspheres in order to obtain an acceptable protein loading, since most sensitive proteins do not tolerate exposure to this or similar organic solvents. Starch microspheres produced from this amylose are not fully biodegraded by α -amylase either in vitro or in vivo.

20 Example 4

Production of amylose from peas.

Amylose was produced by leaching from starch granules. NUTRIO-P-star 33 (300 g, Nordfalk) was suspended in water (7200 g) and the suspension was heated to 75°C for one hour. The swollen granules were removed by centrifuging and the solution obtained was filtered, first through a charcoal filter, then a pre-filter (Filtron, 1.5 μ m) and finally a sterile filter (Millipore, 0.2 μ m). The filtered solution was placed in a refrigerator overnight, the amylose being precipitated and recovered by centrifuging. The precipitate obtained was washed twice with ethanol (95%, 700 ml) and then vacuum-dried. Approximately 30 g of amylose were obtained.

Example 5

Starch microspheres were produced from amylose prepared according to example 4 with a view to analyzing their biodegradability in vitro and in vivo. Since amylose gels too rapidly to permit manual production, a machine was used that permits continuous production. The central unit of the machine is a microwave unit, which permits rapid heating of the starch to approximately 150°C, followed by cooling to around 45°C before mixing with protein solution or buffer solution. The starch solution was prepared in distilled water, since otherwise it turns a brown colour when heated in the microwave unit. The starch was composed of pre-gelatinized amylose from peas (4%) and despite repeated homogenizations a number of lumps remained. The flows were adjusted as follows: starch (5 ml/min), Tris buffer, pH 7.8 (1.2 ml/min) and the PEG solution (2.4 percent by weight PEG with an av. mol. wt. of 300, 000 Da) which also contained 6.9% sodium chloride and 14.3% mannitol. The microparticles were allowed to stabilize at room temperature for some hours and then in a refrigerator overnight. They were recovered by successive washings in a centrifuge: three times with 70% ethanol, three times with 5 mM phosphate-buffered common salt solution containing 1 mM calcium chloride and 0.02% sodium azide, pH 7.4, and finally three times with 99.5% ethanol. The microparticles were vacuum-dried. Since there were some very small particles in the preparation, attempts were made to remove these by threefold sedimentations in 99.5% ethanol, which did not result in complete removal of these. The yield was 8.5 g of particles after the sedimentation, during which 1 g of microspheres was cleaned away.

The particle size distribution was determined with a Malvern Mastersizer and was found to be broad, with the smallest microspheres about 5 µm and the largest over

160 μm . The mean diameter calculated from the volume was 25 μm .

The biodegradability of the starch microspheres was analyzed by incubation with α -amylase in vitro. Initially the degradation was rapid and after one day approximately 35-45% had been converted into soluble form. Thereafter the rate of degradation declined and after 6 days approximately 50% had been dissolved. Thereafter the biodegradability was negligible and after 25 days approximately 50% of the starch microspheres still remained in undissolved form.

This comparative example shows the difficulties involved in producing microspheres from amylose, since it is difficult to make up into homogeneous solutions, requires very high temperatures in order to dissolve and is susceptible to degradation when subjected to these high temperatures, and gels very quickly. The example also shows that the resulting microspheres have far too broad a size distribution, both immediately after manufacture and after attempts to narrow the size distribution, and far too high a content of microspheres with a size of less than 10 μm to be well suited to sustained release after subcutaneous or intramuscular injection. The example also shows that the biodegradability, analyzed in vitro, is incomplete.

Example 6

Analysis of the biodegradability in vivo of starch microspheres produced from amylose.

Starch microspheres (3.01 mg) produced from the amylose in example 4 were injected in a volume of 100 μl subcutaneously into the neck of eight rats of the Sprague-Dawley strain that had undergone hypophysectomy. Small nodules could be detected under the skin of all rats at the injection sites 8-9 days after injection. On dissection 9 days after injection, a macroscopic

inspection was undertaken in which small white cysts were found at the injection site in all rats. The macroscopic changes were fixed in 4% phosphate-buffered formaldehyde, embedded in paraffin wax, cut up with a nominal thickness of 5 μ m, stained with haematoxylin and eosin, and examined under an optical microscope. In the paraffin wax sections in which the starch microspheres could be found, they were seen as eosinophil small spheres surrounded by a zone of granulating tissue containing giant cells and the tissue reaction was characterized as a chronic "granulomatous" inflammation in the subcutaneous tissue. Starch microspheres could also be observed inside macrophages.

The test shows that starch microspheres produced from amylose are found in the subcutaneous tissue 9 days after injection and have thus not been biodegraded sufficiently to have been dissolved during that period, and that in any event a proportion of the microspheres was small enough to allow phagocytosis by macrophages.

20 Example 7

Analysis of the biodegradability in vivo of starch microspheres produced from amylose.

Starch microspheres produced from amylose according to example 4 and suspended in 10 ml of phosphate-buffered (5 mM) physiological common salt solution (0.15M), pH 7.2, were injected intramuscularly into the leg of young pigs. Two pigs were dosed with 120 mg of microspheres and two pigs with 600 mg of microspheres. The animals were sacrificed on day 14 and the tissue examined for macroscopic changes and, after the usual embedding and staining processes, for microscopic changes. On day 14 microspheres were found in the tissue to a degree dependent on the dosage. Some microparticles had been subject to phagocytosis by macrophages and giant cells and were found intracellularly, which is indicative of very slow degradation of the microspheres.

The test shows that starch microspheres produced from amylose are found in the intramuscular tissue two weeks after injection, which indicates that the biodegradability of these microspheres is very slow.

5

Example 7b

Starch microspheres were produced from acid-hydrolyzed amylose from potatoes (Reppal PSM60U), which was subjected to ultrafiltration in order to remove low
10 molecular constituents, with a view to analyzing their biodegradability and capacity to incorporate protein without exposing this to an organic solvent. β -lactoglobulin was used as model protein. The starch concentration was 24% and 4 ml of this were mixed with
15 1.6 ml of the protein solution, which had a concentration of 50 mg/ml at 37°C, and mixed with PEG (average molecular weight 100 kDa, 15 %, 4 ml) and stirred to form an emulsion. The microspheres solidified under stirring at room temperature overnight.

20 All the protein leached out of the microspheres during the centrifuge washings in the buffer (5 mM sodium phosphate, pH 7.8). If only isopropyl alcohol or a series consisting firstly of 15% PEG with a mol. wt. of 100, 000, followed by 40% PEG with a mol. wt. of 10, 000 Da and
25 finally isopropyl-alcohol are used, protein corresponding to between 1.5 and 3% could be found in the microspheres. The biodegradability of the microspheres was analyzed in vitro. This was initially rapid and after twenty-four hours approximately 60% of the matrix had been converted
30 into soluble form. Thereafter the degradation ceased, and after 7 days approximately 70% of the matrix had been biodegraded under these conditions.

In order to obtain some loading of the protein into the said microspheres it was necessary to precipitate the
35 protein with an organic solvent, which is not an

acceptable method for sensitive proteins. Nor were the microspheres obtained fully biodegradable in vitro.

Example 7c

5 Starch microspheres were produced from extensively acid-hydrolyzed amylose from potatoes (Reppal PSM25, Reppe, Glykos, Växjö) with a view to analyzing their biodegradability and capacity to incorporate protein without exposing this to an organic solvent. β -
10 lactoglobulin was used as model protein. The starch concentration was 20% and 4 ml of this were mixed with 1.6 ml of the protein solution, which had a concentration of 50 mg/ml at 37°C, and mixed with PEG (average molecular weight 100 kDa, 15 %, 4 ml) and stirred to form an
15 emulsion. The microspheres solidified under stirring at room temperature overnight.

All the protein leached out of the microspheres during the centrifuge washings in the buffer (5 mM sodium phosphate, pH 7.8). If only isopropyl alcohol or a series
20 consisting firstly of 15% PEG with a mol. wt. of 100, 000, followed by 40% PEG with a mol. wt. of 10, 000 Da and finally isopropyl alcohol are used, protein corresponding approximately to between 1.5 and 2.5% could be found in the microspheres. The biodegradability of the
25 microspheres was analyzed in vitro. This was initially rapid and after twenty-four hours approximately 55% of the matrix had been converted into soluble form. Thereafter the degradation ceased, and after 7 days approximately 70% of the starch matrix had been biodegraded under these
30 conditions.

In order to obtain some loading of the protein into the said microspheres it was necessary to precipitate the protein with an organic solvent, which is not an acceptable method for sensitive proteins. Nor were the
35 microspheres obtained fully biodegradable in vitro.

Example 8

Immobilization of BSA with high loading in starch microspheres produced from highly branched, sheared starch.

5 A starch solution (40%) of sheared, highly branched starch with an av. mol. wt. of 1600 kDa, a solution (38%) of PEG 20 000 Da of av. mol. wt. and a solution of BSA (14%) were prepared in 50 mM sodium phosphate, pH 8.3. The temperature of the starch solution was adjusted to 50-
10 55°C, the PEG and BSA solution to approx. 33°C. The starch solution (2g) was mixed with the BSA solution (0.7 ml). The solution obtained was drawn up in a syringe, which was fitted to a syringe pump. A solution of PEG (29g) was mounted in another syringe fitted to
15 another syringe pump. The starch microspheres were produced by pumping the mixtures of starch/BSA and PEG through static mixers by means of the syringe pump down into a beaker where the emulsion is stirred by a propeller (100 rpm). This part of the process took 2 minutes from
20 starting until everything was mixed. The stirring in the beaker was allowed to continue for 10 minutes and the specimen was then shifted to 4°C, where it was allowed to stand under stirring for approx. 4 hours. Thereafter the pH value of the solution was reduced to approx. 5.5 and
25 the preparation was left at 37°C overnight without stirring. The starch microspheres were washed by filtering in an Amicon (Amicon ultrafiltration cell) 5 mM sodium phosphate, pH 4.5, and freeze-dried.

30 The dried microspheres were dissolved by enzyme action with α -amylase and amylo glucosidase for determining the protein and starch yield, and protein loading. The protein yield was 94%, the starch yield 89% and the loading obtained was 10%. The mean particle size determined with a Malvern Mastersizer was 90 μ m and with
35 less than 10% of the distribution below 35 μ m. By incubation with α -amylase or α -amylase and amylo

glucosidase the microspheres were fully dissolved within forty-eight hours.

The example shows that a protein, BSA, can be immobilized with high yield and that the microspheres
5 obtained have a high loading of the protein. The microspheres are biodegradable, since they are completely dissolved by α -amylase in vitro and this can be done under mild conditions, which permits accurate chemical analysis of the immobilized protein without the
10 introduction of artefacts on account of the actual extraction process. The example also shows that all protein entrapped can be recovered after dissolving the microspheres.

15 Example 9

Immobilization of BSA with high loading in starch microspheres produced from highly branched, sheared starch.

Starch microspheres containing BSA were produced by
20 using a starch solution (40%) of sheared, highly branched starch with an average molecular weight of 1600 kDa, a PEG solution (38%, av. mol. wt. 20 000 Da) and a solution of BSA (16%) produced in 50 mM phosphate, pH 8.3. The temperature of the starch solution was adjusted to 50-55°C
25 and the PEG and BSA solution to approx. 30°C. The starch microspheres were produced in an IKA reactor (IKA laboratory reactor LR250). The starch solution (20g) was mixed with the BSA solution (6.7 ml). The PEG solution (290g) was pumped down into the reactor vessel under
30 stirring (100 rpm) for approx. 6 minutes and the stirring was continued for approx. 15 minutes. The preparation was transferred to 4°C and allowed to stand under stirring overnight. The pH value of the solution was reduced to approx. 5.5 and this was transferred to 37°C, where it was
35 allowed to stand for approx. 7 hours without stirring.

The starch microspheres containing BSA were washed with 5 mM sodium phosphate, pH 4.5, and freeze-dried.

The dried microspheres were dissolved by enzyme action with α -amylase and amylo glucosidase for determining the protein and starch yield, and protein loading. The protein yield was 99%, the starch yield 91% and the loading obtained was 11.5%. The mean particle size determined with a Malvern Mastersizer was 48 μ m and with less than 10% of the distribution below 17 μ m. By incubation with α -amylase or α -amylase and amylo glucosidase the microspheres were fully dissolved within forty-eight hours.

Example 10

15 Immobilization of BSA with high loading in starch microspheres produced from highly branched, sheared starch.

A starch solution (20%) of highly branched, sheared starch with av. mol. wt. of 1930 kDa, a PEG solution (38%, av. mol. wt. 20 000 Da) and a BSA solution (20%) were prepared in 50 mM sodium carbonate, pH 9.8. The temperature of the starch solution was adjusted to 50-55°C and the other solutions to approx. 37°C. The starch solution (3g) was mixed with the BSA solution (0.7 ml). The mixture was drawn up in a syringe and added to the PEG solution (28g) in a beaker whilst stirring. The preparation was transferred to 4°C, where it was allowed to stand for 4 hours and thereafter to 37°C, where it was allowed to stand overnight. The starch microspheres containing BSA were washed with 5 mM sodium phosphate, pH 4.5, and freeze-dried.

The dried microspheres were dissolved by enzyme action with α -amylase and amylo glucosidase for determining the protein and starch yield, and protein loading. The protein yield was 91%, the starch yield 90% and the loading obtained was 10.6%. The mean particle

size determined with a Malvern Mastersizer was 44 μm and with less than 10% of the distribution below 21 μm . By incubation with α -amylase or α -amylase and amylo glucosidase the microspheres were fully dissolved within
5 forty-eight hours.

Example 11

Immobilization of crystalline hGH in starch microspheres produced from highly branched, sheared starch with high
10 starch and PEG concentrations and temperature cycling.

Crystals of zinc hGH were produced according to EP 0 540 582 B1. A suspension of the said crystals was prepared in 10 mM sodium acetate, pH 6.4, containing 2 mM zinc acetate.

15 A starch solution (40%) was produced from highly branched, sheared starch with av. mol. wt. 378 kDa in 10 mM sodium phosphate, pH 6.4, and a PEG solution with av. Mol. Wt. 20, 000 at a concentration of 30%. This was adjusted to pH 6.4 with 1 M HCl. The temperature of the
20 solutions was adjusted as follows: the starch solution to 50-55°C, the PEG solution to 37°C and the suspension of Zn-hGH crystals to 37°C. 4.9 g of the starch solution was added to 7 ml of the suspension of Zn-hGH crystals whilst stirring. After approx. 20 seconds, 28 g of the PEG
25 solution was added by means of a syringe pump for approx. 6 minutes, whilst continuing to stir at 400 rpm (Eurostar digital). The microspheres began to form immediately and after approx. 15 minutes were moved from 37°C to 4°C, and were kept there for 4 hours under stirring. After
30 stabilizing for 4 hours, the microspheres were so stable that they could be transferred to 37°C and kept there without stirring overnight. The microspheres obtained were washed three times with 10 mM sodium acetate, pH 6.4, containing 2mM zinc acetate, after having been stabilized
35 at 37°C for approx. 17-20 hours by filtering in an Amicon, and freeze-dried.

The dried microspheres were dissolved by enzyme action with α -amylase and amylo glucosidase for determining the protein and starch yield, protein loading and protein quality. The protein yield was 95.2%, the
5 starch yield 68% and the protein loading in the microspheres was 27.8%. The mean particle size determined with a Malvern Mastersizer was 59 μm and with less than 10% of the distribution below 29 μm . By incubation with α -amylase or α -amylase and amylo
10 glucosidase the microspheres were fully dissolved within forty-eight hours. The dimer content of the protein was 0.75% and polymer content <0.1%.

The test shows that even proteins that have been converted into solid form can be immobilized with high
15 yield and resulting in starch microspheres with high loading of the protein according to the present invention. The test also shows that the starch microspheres obtained can be dissolved under mild conditions, which permits rigorous quality control of the characteristics of the
20 immobilized protein without the introduction of artefacts deriving from trial preparation, and that the protein is not degraded in the process. The protein quality obtained is acceptable for parenteral administration to humans.

25 Example 12

Immobilization of BSA in starch microspheres of highly branched, sheared starch and analysis of the biodegradability in vivo.

Starch microspheres containing BSA were produced from
30 highly branched, sheared starch with av. mol. wt. 1930 kDa under the following conditions: the starch (30%, 100 ml) was mixed with PEG (38%, 1466 ml, av. mol. wt. 20 kDa) and stirred, first for 6 hours at 20°C and then overnight at 37°C. These were administered subcutaneously and
35 intramuscularly to rats in a dosage of 30 mg in an injection vehicle composed of 0.6% sodium hyaluronic acid

(mol. wt. 2000 kDa, Kraeber GmbH, Hamburg) and the injection site was prepared for histological analysis after 3 and 7 days. On day 3, cellular infiltration at the injection site was observed, and these changes had
5 already disappeared by day 7.

This test shows that starch microspheres produced from highly branched, sheared starch are biodegraded rapidly, within one week, in vivo and that the tissue is rapidly normalized.

10

Example 13

Determination of the biodegradability of starch microspheres in pigs.

Starch microspheres were produced from sheared starch
15 with an av. mol. wt. of 529 kDa. The starch was weighed into 10 mM of sodium phosphate, pH 6.4, so that the concentration after dissolving was 30% and PEG 20 with an av. mol. wt. in the same buffer so that the final concentration after dissolving was 27%. The solutions
20 were then prepared by autoclaving. Production was performed in an IKA reactor with Eurostar digital stirring control (Labasco). 14.35 g of the starch solution were used for the production and this was kept warm at 50°C after dissolving, after which 200 g of the PEG solution
25 was fed to the reactor. The emulsion was formed by stirring at 160 rpm with a propeller and after 8 minutes the stirring speed was adjusted to 140 rpm, and after 5 hours to 110 rpm, and the temperature was set to 20°C for 7 hours and thereafter 38°C for 17 hours. The starch
30 microspheres obtained were then washed (Amicon ultrafiltration unit 8400) four times with 300 ml of water and freeze-dried. The dry starch microspheres were sieved (Retsch sieveing machine) with 38 and 100 µm screens. The total quantity of starch microspheres that was obtained
35 prior to sieveing was 3.61 g, which corresponds to a yield

of approximately 86%, and after sieving 2.54 g, which corresponds to a yield of approx. 59%.

The starch microspheres were resuspended in 1 ml of 0.11% sodium hyaluronic acid, 4% mannitol, in water for
5 injection and 100 mg of microspheres were injected subcutaneously into pigs. The injection site was prepared for histological evaluation. No starch microspheres could be observed 7 days after injection.

This test shows that the starch microspheres were
10 biodegraded rapidly and disappeared from the injection site within one week.

PATENT CLAIMS

1. A process for producing parenterally, preferably by injection, administrable microparticles
5 containing a biologically active substance, which process comprises:
- a) preparing an aqueous starch solution, comprising starch which has an amylopectin content exceeding 85% by weight, in which the molecular weight of the said
10 amylopectin has been reduced such that at least 80% by weight of the material is within the range of 10-10 000 kDa, and which has an amino acid nitrogen content of less than 50 µg per g dry weight of starch, the starch concentration of the solution being at least 20% by
15 weight,
 - b) combining the biologically active substance with the starch solution under such conditions that a composition in the form of a solution, emulsion or suspension of said substance in the starch solution is
20 formed,
 - c) mixing the composition obtained in step b) with an aqueous solution of a polymer having the ability of forming a two-phase aqueous system, thereby forming an emulsion of starch droplets which contain the
25 biologically active substance as an inner phase in an outer phase of said polymer solution,
 - d) causing or allowing the starch droplets obtained in step c) to gel into starch particles through the natural capacity of the starch to solidify,
 - 30 e) drying the starch particles, preferably after prior removal of said outer phase through washing, and
 - f) optionally applying a release-controlling shell of a biocompatible and biodegradable polymer, preferably by air suspension technology, to the dried starch
35 particles.

2. A process according to Claim 1, in which the

starch has a purity of at most 20 µg, preferably at most 10 µg, and more preferably at most 5 µg, amino acid nitrogen per g dry weight of starch.

3. A process according to Claim 1 or 2, in which
5 the starch has an amylopectin content with said reduced molecular weight exceeding 95% by weight, preferably exceeding 98% by weight.

4. A process according to any one of the preceding claims, in which the molecular weight of said amylopectin
10 is reduced such that at least 80% by weight of the material is within the range of 100-4 000 kDa, preferably 200-1 000 kDa, and more preferably 300-600 kDa.

5. A process according to any one of the preceding claims, in which the starch is such that it can be
15 dissolved in a concentration exceeding 25% by weight in water.

6. A process according to any one of the preceding claims, in which the starch is essentially lacking in covalently bonded extra chemical groups of the type which
20 are found in hydroxyethyl starch.

7. A process according to any one of the preceding claims, in which the starch has an endotoxin content of less than 25 EU/g and contains less than 100 microorganisms per gram.

25 8. A process according to any one of the preceding claims, in which the starch is essentially purified from surface-localized proteins, lipids and endotoxins by means of washing with aqueous alkali solution, reduced in molecular weight by means of shearing, and purified from
30 internal proteins by means of ion exchange chromatography, preferably anion exchange chromatography.

9. A process according to any one of the preceding claims, in which in step a) 2-15% by weight amylose is also used as a starch, having an average molecular weight
35 within the range of 2.5-70 kDa, preferably 5-45 kDa, in which the percentage share by weight is calculated on the

basis of dry weight of starch.

10. A process according to any one of the preceding claims, in which in step a) a solution is prepared having a starch concentration of at least 30% by weight.

11. A process according to any one of the preceding claims, in which in step a) a solution is prepared having a starch concentration of at most 50% by weight, preferably at most 45% by weight.

12. A process according to any one of the preceding claims, in which the aqueous starch solution in step a) is prepared with accompanying autoclaving of the same.

13. A process according to any one of the preceding claims, in which in step b) the active substance is combined with the starch solution at a temperature of at most 60°C, preferably 20-45°C, especially 30-37°C.

14. A process according to any one of the preceding claims, in which in step b) a composition is formed in which the weight ratio between starch and biologically active substance is within the range of 3:1 to 10 000:1, preferably 3:1 to 100:1.

15. A process according to any one of the preceding claims, in which in step c) the polymer is used in a concentration in said aqueous solution of at least 20% by weight, preferably at least 30% by weight.

16. A process according to any one of the preceding claims, in which in step c) the polymer is used in a concentration in said aqueous solution of at most 45% by weight, preferably 30-40% by weight.

17. A process according to any one of the preceding claims, in which the mixing in step c) is performed at a temperature within the range of 4-50°C, preferably 10-40°C, especially 10-37°C.

18. A process according to any one of the preceding claims, in which the mixing in step c) is

performed with the aid of at least one static mixer.

19. A process according to any one of the preceding claims, in which in step c) the polymer solution is added to the composition in at least two steps, in which at least one of the additions is effected after the emulsion has begun to be created.

20. A process according to any one of the preceding claims, in which in step c) polyethylene glycol is used as the aqueous polymer.

21. A process according to Claim 20, in which the polyethylene glycol has an average molecular weight of 5-35 kDa, preferably 15-25 kDa, especially about 20 kDa.

22. A process according to any one of the preceding claims, in which the solidification in step d) is performed at at least two temperatures, in which the initiation is effected at a lower temperature than the termination.

23. A process according to Claim 22, in which the solidification is initiated within the range of 1-20°C, preferably 1-10°C, especially around 4°C, and is terminated within the range of 20-55°C, preferably 25-40°C, especially around 37°C.

24. A process according to any one of the preceding claims, in which the drying in step e) is performed in the form of spray-drying, freeze-drying or vacuum-drying, preferably freeze-drying.

25. A process according to any one of the preceding claims, in which, as the biologically active substance, a substance is incorporated which is chosen from the group consisting of proteins, peptides, polypeptides, polynucleotides and polysaccharides, especially recombinantly produced proteins.

26. A process according to any one of the preceding claims, in which said substance is selected from growth factors, insulin, erythropoietin, interferon α , interferon β , interferon γ , blood coagulation factors V,

VI, VII, VIII, IX, X, XI, XII and XIII, protein C, glucagon-like peptide 1 or 2, C-peptide, epidermal growth factor, growth hormone, LHRH-analogues, civamide, macrophage colony-stimulating factor, granulocyte colony-stimulating factor, leptin and interleukin, or an analogue or derivate of any one thereof, which possesses essentially the same pharmacological activity as the parent substance or improved pharmacological activity as compared thereto.

10 27. A process according to any one of the preceding claims, in which in step c) starch droplets are formed which give the size required for the microparticles, preferably a mean particle diameter, in the dry state, within the range of 10-200 μm , preferably
15 20-100 μm , more preferably 20-80 μm .

28. A process according to any one of the preceding claims, in which after step d) the microparticles are washed, through filtration, and optionally sieved in order to obtain the desired particle
20 size distribution.

29. Microparticles suitable for parenteral administration, preferably via injection, to a mammal, especially a human, and containing a biologically active substance, which microparticles essentially consist of
25 starch having an amylopectin content exceeding 85% by weight, of which at least 80% by weight has an average molecular weight within the range of 10-10 000 kDa and having an amino acid nitrogen content of less than 50 μg per gram dry weight of starch, and which have no covalent
30 chemical cross-linking between the starch molecules.

30. Microparticles according to Claim 28, in which the starch is of the kind defined in any one of Claims 2-9.

31. Microparticles according to any one of Claims
35 29 and 30, in which the bioactivity of the biological substance is at least 80%, preferably at least 90% and

more preferably essentially maintained compared with the bioactivity exhibited by the substance prior to its incorporation in the starch.

32. Microparticles according to any one of Claims
5 29-31, which are biodegradable in vitro in the presence of alpha-amylase and/or amyloglucosidase.

33. Microparticles according to any one of Claims 29-32, which are biodegradable and are eliminated from tissue after subcutaneous or intramuscular administration.

10 34. Microparticles according to any one of Claims 29-33, which have a release-controlling shell of at least one film-forming biocompatible and biodegradable polymer.

35. Microparticles according to Claim 34, in which the polymer is a homopolymer or copolymer containing
15 alpha-hydroxy acid units.

36. Microparticles according to Claim 35, in which the alpha-hydroxy acid is lactic acid and/or glycolic acid.

37. Microparticles according to any one of claims
20 34-36, in which said shell contains at least one release regulating substance, in addition to said polymer.

38. Microparticles according to claim 37, in which said substance is water soluble or sparingly water soluble.

25 39. Microparticles according to any one of claims 37 and 38, in which said substance is selected from lactic acid, oligomers containing lactic acid and glycolic acid.

40. Microparticles according to any one of claims 37 and 38, in which said substance comprises polyethylene glycol (PEG) or a block copolymer comprising PEG as one of
30 the blocks.

41. Microparticles according to any one of claims 29-40, which have an outer layer of at least one water soluble substance having the ability to prevent
35 aggregation of the microparticles.

42. Microparticles according to any one of claims

29-41, which are injectable using a 23 G needle.

43. Microparticles according to any one of claims
29-42, which are injectable using a 25 G needle.

44. Microparticles according to any one of claims
5 29-41, which are injectable through the skin using a dry
powder injection.

45. Microparticles according to any one of claims
29-41, which are injectable by means of a needle-free
injector.

10 46. Microparticles according to any one of claims
29-45, which are obtainable by means of a process
according to any one of claims 1-28.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/02164

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 9/16, A61K 9/50, B01J 13/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, B01J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, CHEM ABS DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4713249 A (ULF SCHRÖDER), 15 December 1987 (15.12.87) --	1-46
A	US 5455342 A (BRUCE K, REDDING, JR.), 3 October 1995 (03.10.95) --	1-46
A	US 5792477 A (MICHAEL E. RICKEY ET AL), 11 August 1998 (11.08.98) --	1-46
A	WO 9900425 A1 (RUTGERS UNIVERSITY), 7 January 1999 (07.01.99) --	1-46

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 February 2002

Date of mailing of the international search report

18 5 -02- 2002

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Anna Sjölund/EÖ

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/02164

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9920253 A1 (BIOGLAN THERAPEUTICS AB), 29 April 1999 (29.04.99) -- -----	1-46

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE 01/02164

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	4713249	A	15/12/87	AU	9127482 A	01/06/83
				EP	0093757 A	16/11/83
				US	4501726 A	26/02/85
				WO	8301738 A	26/05/83
				AT	34659 T	15/06/88
				AU	567434 B	19/11/87
				AU	1776083 A	08/02/84
				DE	3376797 D	00/00/00
				DK	95284 A	23/02/84
				EP	0113749 A,B	25/07/84
				FI	840923 A	07/03/84
				NO	840676 A	22/02/84
				SE	8204244 A	10/01/84
				WO	8400294 A	02/02/84
US	5455342	A	03/10/95	AU	4109493 A	18/11/93
				WO	9321008 A	28/10/93
US	5792477	A	11/08/98	AU	733199 B	10/05/01
				AU	2897297 A	26/11/97
				BG	102854 A	31/05/99
				BR	9709217 A	10/08/99
				CA	2251987 A	13/11/97
				CN	1226821 A	25/08/99
				CZ	9803591 A	17/03/99
				EE	9800383 A	15/04/99
				EP	0904063 A	31/03/99
				IL	126509 D	00/00/00
				JP	2000503663 T	28/03/00
				NO	984808 A	06/01/99
				PL	329720 A	12/04/99
				SK	154198 A	07/05/99
				US	5916598 A	29/06/99
				US	6110503 A	29/08/00
				US	6290983 B	18/09/01
				WO	9741837 A	13/11/97
				ZA	9703891 A	07/11/97
WO	9900425	A1	07/01/99	AU	8173698 A	19/01/99
				US	5959102 A	28/09/99
WO	9920253	A1	29/04/99	AU	732891 B	03/05/01
				AU	9467098 A	10/05/99
				EP	1033973 A	13/09/00
				HU	0004732 A	28/05/01
				JP	2001520186 T	30/10/01
				NO	310177 B	05/06/01
				NO	20002039 A	13/06/00
				SE	512663 C	17/04/00
				SE	9703874 A	24/04/99
				ZA	9809199 A	15/04/99